Oral bisphosphonates in polyostotic fibrous dysplasia

V V Khadilkar; A V Khadilkar; G B Maskati

Oral bisphosphonates in polyostotic fibrous dysplasia

Indian Pediatr. 2003 Sep;40(9):894-6.

Authors

V V Khadilkar¹, A V Khadilkar, G B Maskati

Affiliation

¹ Growth and Pediatric Endocrine Unit, Hirabai Cowasji Jehangir Medical Research Institute, Jehangir Hospital, 32 Sassoon Road, Pune 411 004, India. [email protected]

PMID: 14530553

Abstract

The bisphosphonates inhibit osteoclastic bone resorption and have been used as an intravenous infusion in fibrous dysplasia of the bone. Oral bisphosphonates are cheaper and also easy to administer. We report a case of polyostotic fibrous dysplasia in a three-year-old child who showed significant improvement in bone mineral density after treatment with oral alendronate.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Alendronate / pharmacology
Alendronate / therapeutic use*
Bone Density / drug effects
Child, Preschool
Fibrous Dysplasia, Polyostotic / drug therapy*
Humans
Male

Substances

Alendronate